27381 Phase III, randomized trial comparing clinical outcomes between patients with moderate-to-severe chronic plaque psoriasis receiving adalimumab reference product (RP) continuously vs those who switched between BI 695501 and adalimumab RP

2021 ◽  
Vol 85 (3) ◽  
pp. AB140
Author(s):  
Alan Menter ◽  
Dorothy McCabe ◽  
Benjamin Lang ◽  
Jennifer Schaible ◽  
Sravan Kumar Eduru
Keyword(s):  
Randomized Trial ◽  
Clinical Outcomes ◽  
Plaque Psoriasis ◽  
Reference Product ◽  
Phase Iii ◽  
Chronic Plaque Psoriasis

Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada

2014 ◽  
Vol 18 (6) ◽  
pp. 371-378 ◽  
Author(s):  
Aditya K. Gupta ◽  
Deanne Daigle ◽  
Danika C.A. Lyons
Keyword(s):  
Clinical Trials ◽  
Plaque Psoriasis ◽  
Meta Analysis ◽  
Severity Index ◽  
Phase Iii ◽  
Chronic Plaque Psoriasis ◽  
Phase Iii Clinical Trials ◽  
Statistical Framework ◽  
Consistency Model ◽  
Systemic Treatments

Background: Psoriasis affects approximately 500,000 Canadians. Eight treatments are currently licensed for chronic plaque psoriasis in Canada. Objective: To compare the efficacy of systemic treatments for chronic plaque psoriasis for the outcome > 75% reduction in the Psoriasis Area and Severity Index (PASI) using network meta-analysis. Methods: PubMed and clinicaltrials.gov databases were searched up until October 15, 2013, for phase III clinical trials. A consistency model based on a random-effects bayesian statistical framework was used to compare the rates of > 75% PASI reduction across trials. Results: Twenty-one studies were included in the network analysis. Infliximab had significantly greater odds of producing > 75% reduction in the PASI compared to all treatments. All treatments conferred greater odds of > 75% PASI reduction compared to placebo. Conclusion: Although infliximab had the highest efficacy relative to other systemic treatments for psoriasis, adverse effects, cost, and patient preferences should also be considered when deciding on treatment.

Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis

2015 ◽  
Vol 55 (3) ◽  
pp. e147-e155 ◽  
Author(s):  
Bruce Strober ◽  
Yang Zhao ◽  
Mary Helen Tran ◽  
Ari Gnanasakthy ◽  
Judit Nyirady ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Study Data ◽  
Phase Iii ◽  
Psychometric Validation ◽  
Chronic Plaque Psoriasis ◽  
Phase Iii Study ◽  
Symptom Diary

Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial

2005 ◽  
Vol 52 (3) ◽  
pp. 425-433 ◽  
Author(s):  
Craig L. Leonardi ◽  
Kim A. Papp ◽  
Kenneth B. Gordon ◽  
Alan Menter ◽  
Steven R. Feldman ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Phase Iii ◽  
Chronic Plaque Psoriasis ◽  
Phase Iii Trial
Sign in / Sign up

Export Citation Format

Share Document